UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
December 13, 2004
Date of Report (Date of earliest event reported)
CONNETICS CORPORATION
| Delaware (State or Other Jurisdiction of Incorporation) |
0-27406 (Commission File No.) |
94-3173928 (IRS Employer Identification No.) |
3290 West Bayshore Road, Palo Alto, California 94303
(Address of principal executive offices, including zip code)
(650) 843-2800
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||
| Item 8.01. Other Events. | ||||||||
| Item 9.01 Financial Statements and Exhibits. | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| EXHIBIT 99.1 | ||||||||
Item 8.01. Other Events.
On December 13, 2004, Connetics Corporation (“Connetics”) announced the U.S. commercial launch of Evoclin ™ (clindamycin 1%) delivered in Connetics’ proprietary VersaFoam® vehicle for the treatment of acne vulgaris. Evoclin is the first product approval in the acne market for Connetics, and is available in 50g and 100g trade unit sizes as well as 10g professional samples. A copy of the Connetics press release regarding Evoclin is attached as Exhibit 99.1 and is incorporated by reference in this Item 8.01.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits
| Exhibit | ||
| Number |
Description |
|
99.1
|
Press Release dated December 13, 2004 regarding Evoclin. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CONNETICS CORPORATION | ||||
| By: | /s/ Sanjiv S. Dhawan | |||
| Sanjiv S. Dhawan | ||||
| Vice President, Corporate Counsel | ||||
Date: December 15, 2004